CHIMERIX INC: insider trades · United States · SEC (Form 4)

About CHIMERIX INC

Chimerix Inc. (NASDAQ: CMRX) is a United States-based biopharmaceutical company listed on the NASDAQ market in the United States, headquartered in Durham, North Carolina. For investors, the company represents a specialty healthcare name focused on developing novel therapies for severe diseases, with its current strategic identity centered on oncology and rare-disease drug development. Chimerix was founded in 2000 and originally built its platform around antiviral technologies before gradually shifting its portfolio toward higher-value clinical programs, especially in oncology. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage?utm_source=openai)) Today, Chimerix’s core value driver is its lead asset, dordaviprone, also known as ONC201. The company describes it as a first-in-class small-molecule imipridone being developed for H3 K27M-mutant diffuse glioma, a rare and highly aggressive brain tumor with substantial unmet medical need. In February 2025, Chimerix announced that the FDA had accepted its New Drug Application and granted Priority Review, with a PDUFA target action date of August 18, 2025. That regulatory milestone is central to the investment case and could be transformative if it results in approval. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai)) From a competitive standpoint, Chimerix is a highly focused biotech rather than a diversified pharmaceutical group. Its narrow pipeline increases concentration risk, but it also gives the company meaningful operating leverage if dordaviprone succeeds commercially. Management has highlighted the drug’s potential to become the first approved therapy specifically for recurrent H3 K27M-mutant diffuse glioma, which would create an important first-mover position in a small but medically urgent market. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai)) Historically, Chimerix began as an antiviral company, building around oral antiviral candidates such as brincidofovir. Over time, the company reallocated capital toward oncology, notably through the 2021 acquisition of Oncoceutics, which brought ONC201 into the portfolio. It also monetized TEMBEXA in 2022, underscoring a strategic pivot toward its lead clinical oncology asset. This sequence suggests a company that has deliberately narrowed its scope to maximize the probability of creating value around its most promising program. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage?utm_source=openai)) Geographically, Chimerix operates primarily from the United States and collaborates with clinical sites in the U.S. and abroad for its development programs. Recent 2025 company communications have emphasized regulatory progress and preparation for a potential commercial launch. For market participants, Chimerix should be viewed as a catalyst-driven biotech where valuation is likely to be highly sensitive to FDA outcomes, clinical data, and commercialization execution in H3 K27M-mutant diffuse glioma. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai))